A Sluggish Man's Way To The Cyclopamine Profits

AlloSCT may provide long term remission in some pts, but requires good remission at entry. We have treated http://www.selleckchem.com/products/Cyclopamine.html 37 such pts with brentuximab vedotin (BV) and 10 have undergone subsequent alloSCT. Methods: Criteria for commencing BV included PD to salvage therapy or PD post autoSCT. Demographics and disease history are shown in the table below: Abstract 511 Table. Female/Male 7/3 Median age (range) 38 (23-62) Histology 7 HL, 3 ALCL Stage 2A- 4BX Median prior therapies (range) 3 (2-6 ) Prior radiotherapy 4 Prior AutoSCT 4 Refractory to last therapy (PD http://www.selleckchem.com/products/BI-2536.html 2 PRs converted http://www.selleck.cn/products/gsk126.html to CR. 1 PR experienced PD in the BM at d+30, but was in CR by d+100 following withdrawal of ciclosporin. The pt in PD died of viral reactivation at d+81. AlloSCT toxicity included GvHD: G3 (2 pts), G2 (6 pts). 1 pt had bone infarcts presenting as joint pain, 1 pt has unexplained anaemia. At median follow-up of 406 days from alloSCT, 9 of 10 pts are alive and disease free. 100 day and 1 year actuarial PFS is 77.8% [36.3-93.9] and OS 88.9% [43.3-98.4] at both time points. Non relapse mortality is 11.1% Conclusions: BV followed by alloSCT is well tolerated and produces excellent early disease control in pts with relapsed/refractory HL/ALCL and a dismal predicted prognosis using conventional treatment. Longer follow-up is required to determine the impact of this approach on disease control and late treatment effects at 2 and 5 years. 512 PROGNOSTIC FACTORS FOR SURVIVAL IN LYMPHOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. P. Samaras,1 D. Zardavas,1 U. Petrausch,1 E. M. Buset,1 S. Haile,2 H. Honegger,3 R. D. Siciliano,3 U. Schanz,4 A. Mischo,1 N. G. Schaefer,5 C. Taverna,1 A. Knuth,1 R. Stahel,1 F. Stenner-Liewen,1 C. Renner.